(PharmaNewsWire.Com, January 22, 2018 ) The Global Melanoma Therapeutics Market was worth $2.22 billion in 2016 and estimated to be growing at a CAGR of 15.80%, to reach $4.63 billion by 2021. The market for skin diseases and treatment is expanding substantially due to the mounting frequency of skin ailments such as skin cancer, skin infections, and skin allergies.
Melanoma denotes to the type of skin cancer which forms from the pigment-consisting cells in the skin. It is more frequent in places with a sunny environment and is the most dangerous of all skin cancers. UV radiations are the main causes of melanoma. However, genes can also lead to melanoma. Treatments accessible for melanoma include surgery, radiation therapy, immunotherapy, and chemotherapy.
The growth of the Global Melanoma Therapeutics Market is mainly driven by factors such as rise in melanoma cases, increasing awareness, high acceptance rate of therapeutics among patients, and government policies to provide better care for melanoma. However, high costs incurred due to treatments and poor availability of proper cancer care in the emerging regions are hindering the growth of the market.
The Global Melanoma Therapeutics market is segmented based on cancer stage, cancer type, diagnosis, and treatment. The market for Melanoma Therapeutics, on the basis of cancer stage is segmented into Stage 0, Stage I, Stage II, Stage III, Stage IV. On the basis of cancer type, the global Melanoma Therapeutics market is segmented into Nodular melanoma, Acral lentiginous melanoma, Superficial spreading melanoma, Lentigno maligna melanoma, Amelanotic melanoma, and Others. On the basis of diagnosis, the global Melanoma Therapeutics market is segmented into Ultrasound, Blood Tests, Dermatoscopy, Sentinel lymph node biopsy, X-rays, CT Scan. On the basis of treatment, the global Melanoma Therapeutics market is segmented into early melanoma and advanced melanoma. Advanced melanoma is further sub-segmented into Biological therapy, Targeted therapy, Surgery, Chemotherapy, Radiotherapy, Immune therapy. X-rays leads the Global Melanoma Therapeutics market under the diagnosis segment, whereas chemotherapy leads the market under the treatment segment.
The market has also been geographically segmented into North America, Europe, Asia-Pacific and the Rest of the World. North America accounted for the largest share in the global Melanoma Therapeutics due to the increasing frequency of melanoma cases and technological advancements in this region. However, The Asia-Pacific region, which consists of countries such as China and India is projected to grow substantially due to the large population base and rising prevalence of melanoma in these countries. The major companies dominating the Melanoma Therapeutics market are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialties with competitive pricing options.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
